SM 04690

Drug Profile

SM 04690

Alternative Names: SM-04690

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Samumed
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Clinical Phase Unknown Intervertebral disc degeneration

Most Recent Events

  • 15 Nov 2016 Samumed files an IND application with the FDA in USA for Intervertebral disc degeneration
  • 15 Nov 2016 Samumed plans a phase I trial for Intervertebral disc degeneration in USA
  • 11 Nov 2016 Updated efficacy data from a phase I trial in Osteoarthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top